IDH1 and astrocytoma (excluding glioblastoma): On two validation sets that had patient outcome data, patients with IDH-wildtype gliomas that were predicted to be IDH-mutant astrocytomas demonstrated significant (p = 0.016, Jonsson et al., log-rank) or marginally significant (p = 0.073, TCGA validation, log-rank) improvement in survival compared to correctly predicted IDH-wildtype gliomas (Fig. 5E, F).